China Biotech Services Holdings Limited announced that, on 18 October 2023, after trading hours, the Company and AstraZeneca Investment (China) Co., Ltd. entered into a strategic cooperation framework agreement (the "Framework Agreement"), pursuant to which the Parties have agreed to cooperate with respect to the development of (i) enhancement,
commercialisation and licensing of immune cell therapy; (ii) design, planning and ecological construction of the R&D and production base; and (iii) cooperation models with innovative platforms (the "Cooperation"). Term: Two (2) years from the date on which the Framework Agreement is signed. The Parties specifically agreed to cooperate on the following (among other matters): the Parties will actively discuss immune cell therapy cooperation with a "patient-centered" approach, and conduct in-depth discussions on technology licensing cooperation and commercial development around the fourth-generation costimulation-enhanced CAR T-OX40 development platform developed by Shanghai Longyao Biotech Company Limited; the Parties will conduct in-depth discussions on the design, planning and ecological constructions of an immune cell new drug R&D and production base; and the Parties will actively explore cooperation model with AstraZeneca's global life sciences innovation incubation platform and innovation park. AstraZeneca (China) has built a strategic source and health innovation ecosystem in China that integrates R&D, production, operations, innovation, capital and talents. Shanghai Longyao is one of the pioneers in China to develop CD20-directed autologous chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignances.